Sentien Biotechnologies CEO Brian Miller was featured on the front page of BioWorld™ Today on September 15, 2016. Mr. Miller participated on a Biopharm America panel discussing “How to [...]
Delivering on the promise of cell therapy
Sentien Biotechnologies, Inc. is a privately owned, late preclinical stage company developing novel approaches to cell therapy.
Our lead product, the Sentinel™, is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.